Capula Management’s Sage Therapeutics SAGE Stock Holding History

Capula Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,014	Closed	-$222K	–	670
2021 Q3	$222K	Buy	+5,014	New	+$230K	﹤0.01%	777

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capula Management's SAGE Position: Q4 2021 in Review

Capula Management sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 5,014 shares — an estimated $222K sold.

Capula Management first reported a position in SAGE in Q3 2021 and held it in 1 quarter. The position peaked at $222K in Q3 2021. 216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

Capula Management reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
Capula Management sold 5,014 Sage Therapeutics shares in Q4 2021, an estimated $222K.
Capula Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 1 quarter.
Capula Management's Sage Therapeutics position peaked at $222K in Q3 2021.
216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Capula Management's 13F filing for Q4 2021, filed 14 Feb 2022.